Literature DB >> 7952564

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.

L Chapuis1, B Ji, C Truffot-Pernot, R J O'Brien, M C Raviglione, J H Grosset.   

Abstract

The effectiveness of intermittent administration of rifapentine (RPT), with or without isoniazid (INH), for preventive therapy of tuberculosis was evaluated in immunocompetent (normal) and nude mice. After infection with a small inoculum of Mycobacterium tuberculosis H37Rv, normal mice developed a chronic and nonfatal infection, and the bacterial population became relatively stable after an initial period of limited multiplication. On the other hand, nude mice developed an acute and fatal infection, and all untreated mice died within 5 wk, with very high colony-forming-unit (CFU) counts in their organs. Various degrees of bactericidal activity were shown in normal mice after daily treatment with rifampin (RMP) plus pyrazinamide (PZA) for 13 wk, INH daily for 26 wk, or RPT once weekly for 13 or 26 wk or once fortnightly for 26 wk. The activity of RPT was significantly enhanced when INH was added at the same dosing frequency. In nude mice the response of M. tuberculosis infection to certain regimens was less favorable than that in normal mice, suggesting that preventive therapy may be less effective in severely immunodeficient hosts even during treatment. After chemotherapy was stopped, virtually all nude mice relapsed within 12 wk regardless of the regimen administered, whereas no or very few relapses were observed in normal mice that had been treated with RMP+PZA daily for 13 wk, or RPT alone or RPT+INH once weekly for 26 wk. The latter three regimens and RPT+INH once weekly for 13 wk may be applied for fixed-duration preventive therapy in human immunodeficiency virus (HIV)-negative subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952564     DOI: 10.1164/ajrccm.150.5.7952564

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

1.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

2.  Rifapentine is active in vitro and in vivo against Toxoplasma gondii.

Authors:  F G Araujo; A A Khan; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.

Authors:  A M Lenaerts; S E Chase; A J Chmielewski; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.

Authors:  E Miyazaki; R E Chaisson; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

5.  Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.

Authors:  N Lounis; A Bentoucha; C Truffot-Pernot; B Ji; R J O'Brien; A Vernon; G Roscigno; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.

Authors:  A M Lenaerts; S E Chase; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Authors:  J V Brooks; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 8.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

9.  Clarithromycin is inactive against Mycobacterium tuberculosis.

Authors:  C Truffot-Pernot; N Lounis; J H Grosset; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Authors:  Mauro Schechter; Roberto Zajdenverg; Gisely Falco; Grace Link Barnes; José Cláudio Faulhaber; Jacqueline S Coberly; Richard D Moore; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2006-02-10       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.